Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib.
about
A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignanciesNetwork pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles.Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients.Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles.
P2860
Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Gene expression signatures ass ...... itors, nilotinib and imatinib.
@en
Gene expression signatures ass ...... itors, nilotinib and imatinib.
@nl
type
label
Gene expression signatures ass ...... itors, nilotinib and imatinib.
@en
Gene expression signatures ass ...... itors, nilotinib and imatinib.
@nl
prefLabel
Gene expression signatures ass ...... itors, nilotinib and imatinib.
@en
Gene expression signatures ass ...... itors, nilotinib and imatinib.
@nl
P2093
P2860
P356
P1433
P1476
Gene expression signatures ass ...... itors, nilotinib and imatinib.
@en
P2093
P2860
P2888
P356
10.1038/BCJ.2011.32
P577
2011-08-26T00:00:00Z